true 0001878313 0001878313 2023-02-13 2023-02-13

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  

Washington, D.C. 20549

 

FORM 8-K/A

(Amendment No. 1) 

 

Current Report  

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

February 13, 2023

Date of Report (Date of earliest event reported)

 

MAIA Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-41455

 

83-1495913

(State or other jurisdiction
of incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

444 West Lake Street, Suite 1700

Chicago, IL

 

60606

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (312) 416-8592

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which
registered

Common Stock

 

MAIA

 

NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


 

 

 

Explanatory Note

 

On February 13, 2023, MAIA Biotechnology, Inc. (the “Company”) filed a Current Report on Form 8-K to furnish a copy of the Company’s press release announcing its intention to initiate its second Phase 2 clinical trial evaluating THIO.  On the same day, the Company updated the press release to include an additional model with pre-clinical data.  This amended Current Report on Form 8-K is being filed solely to furnish the updated press release.

 

Item 7.01. Regulation FD Disclosure.

 

On February 13, 2023, MAIA Biotechnology, Inc. (the “Company”) issued a press release announcing its intention to initiate its second Phase 2 clinical trial evaluating THIO. Pursuant to Regulation FD, the press release is furnished with this Current Report as Exhibit 99.1.

 

The information set forth in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)

Exhibits:

 

Exhibit No.

 

Description

99.1

 

Press release, dated as of February 13, 2023.

104

 

Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.


 


 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: February 13, 2023

 

 

 

MAIA BIOTECHNOLOGY, INC.

 

 

 

By:

/s/ Vlad Vitoc

 

Name:

Vlad Vitoc

 

Title:

Chief Executive Officer